Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 24;10:1143. doi: 10.1038/s41598-020-57560-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

PDD005 improves cognitive performance in young adult mice. Young adult WT mice were exposed by SC injection to PDD005 at 8 mg/kg/day or vehicle for 28 days. (A,B) Plots illustrating the effect of PDD005 on short-term memory (working memory) in the Y-maze 3–4 weeks after the end of treatment. (A) General activity was estimated by counting the number of arm entries. PDD005 exposition has not shown to induce hyper or hypoactivity. Cognitive abilities were assessed by the percentage of alternation (B). Mann-Whitney tests were performed and **P < 0.01 indicates significant differences between PDD005 and control conditions. Data expressed as means ± SEM with n = 15 mice/condition. (C) Linear regression analysis shows a positive correlation between brain and plasma concentration of PDD005 at 4 weeks at the end of the exposure period. (D) Linear regression analysis shows a positive correlation between brain concentration of PDD005 and short-term memory abilities at 4 weeks after the end of the treatment. Spearman tests were performed and *P < 0.05 and **P < 0.001 indicate significant correlation. Data expressed as means ± SEM with n = 9 mice/condition.